Abstract

Liver allograft rejection remains a significant cause of morbidity and graft failure in liver transplant recipients. Rejection is caused by the recognition of non-self donor alloantigens by recipient T-cells. Antigen recognition results in proliferation and activation of T-cells in lymphoid tissue before migration to the allograft. Activated T-cells have a variety of effector mechanisms including direct T-cell mediated damage to bile ducts, endothelium and hepatocytes and indirect effects through cytokine production and recruitment of tissue-destructive inflammatory cells. These effects explain the histological appearances of typical acute T-cell mediated rejection. In addition, donor specific antibodies, most typically against HLA antigens, may give rise to antibody-mediated rejection causing damage to the allograft primarily through endothelial injury. However, as an immune-privileged site there are several mechanisms in the liver capable of overcoming rejection and promoting tolerance to the graft, particularly in the context of recruitment of regulatory T-cells and promotors of an immunosuppressive environment. Indeed, around 20% of transplant recipients can be successfully weaned from immunosuppression. Hence, the host immunological response to the liver allograft is best regarded as a balance between rejection-promoting and tolerance-promoting factors. Understanding this balance provides insight into potential mechanisms for novel anti-rejection therapies.

Highlights

  • Liver transplantation is currently the only effective treatment for end-stage liver disease

  • The objective of this review is to provide an overview of the main immunological principles governing rejection and tolerance in the liver allograft and to outline current novel therapeutic approaches aiming to induce long lasting immune tolerance after liver transplantation

  • In rejection it is postulated that the non-self major histocompatibility complex (MHC) class I molecules present on the cells of the allograft are unable to maintain the inhibitory killer immunoglobulin-like receptors (KIRs) signal [78]

Read more

Summary

The Immunological Basis of Liver Allograft Rejection

Edited by: Xiao-Kang Li, National Center for Child Health and Development (NCCHD), Japan. Activated T-cells have a variety of effector mechanisms including direct T-cell mediated damage to bile ducts, endothelium and hepatocytes and indirect effects through cytokine production and recruitment of tissue-destructive inflammatory cells. These effects explain the histological appearances of typical acute T-cell mediated rejection. The host immunological response to the liver allograft is best regarded as a balance between rejection-promoting and tolerance-promoting factors. Understanding this balance provides insight into potential mechanisms for novel anti-rejection therapies.

INTRODUCTION
Major Histocompatibility Complex Antigen Expression
Effector Responses
THE IMMUNOLOGICAL BASIS OF ANTIBODY MEDIATED REJECTION
Antibody Production
Antibody Effector Functions
Mesenchymal Stromal Cells
Tolerogenic Antigen Presentation
NK Cells
Polyclonal Polyclonal Donor specific
CONCLUSION
Findings
AUTHOR CONTRIBUTIONS

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.